FT819 in Subjects With B-cell Malignancies
← catalyst calendarSponsored by Fate Therapeutics (industry) · FATE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
54actual
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-12 | actual | When the study began enrolling |
| Primary completion | 2025-06-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2039-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma, B-Cell
- Chronic Lymphocytic Leukemia
- Precursor B-Cell Acute Lymphoblastic Leukemia
Interventions
- Drug: FT819
- Drug: Cyclophosphamide
- Drug: Fludarabine — also filed as Fludara
- Drug: IL-2 — also filed as Interleukin-2
- Drug: Bendamustine — also filed as Bendeka, Treanda
Primary outcomes
what the primary-completion date above is the date OFIncidence and nature of dose-limiting toxicities within each dose level cohort
measured Up to Day 29
Incidence, nature, and severity of adverse events (AEs) of FT819 as monotherapy and in combination with IL-2 in r/r B-cell lymphoma, r/r chronic lymphocytic leukemia, and r/r precursor B-cell acute lymphoblastic leukemia
measured Up to 15 years
Permalink · FATE's whole pipeline · Catalyst calendar · Every registered study · What changed